IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapyYoshiko Okita, Soichiro Shibui, Yoshitaka Narita et al.|International Journal of Oncology|2012Cited by 76
WHOLE EXOME SEQUENCING IDENTIFIED THAT THE MAPK AND PI3K PATHWAYS ARE THE MAIN TARGETS FOR MUTATIONS IN INTRACRANIAL GERM CELL TUMORSK. Ichimura, Ryo Nishikawa, Ayaka Otsuka et al.|Neuro-Oncology|2014Cited by 1